SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors react to volatility surrounding unconfirmed peace talks with Iran and skepticism over the company's long-term business performance. Community discourse is sharply divided, with intense debate occurring between supporters and critics regarding the stock's valuation, broader geopolitical implications of the administration's policies, and the authenticity of recent product and media claims.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is experiencing high social media engagement as fans celebrate regional sports wins and the World Cup, which many believe will drive merchandise demand and boost the stock. While some investors are optimistic about the brand's resilience and potential for an oversold recovery, others remain cautious, debating whether upcoming earnings and global events can offset long-term concerns regarding China sales and competitive market positioning.

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

Lightpath Technologies is attracting significant community attention as investors track its potential as a key supplier for U.S. defense programs like the NGSRI, with discussions centering on whether the company will secure major contract awards as it transitions into a vertically integrated IR systems provider. The stock is experiencing heightened volatility and active trading as shareholders monitor insider activity and look toward upcoming earnings for confirmation of backlog conversion and strategic growth.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors monitor the high-stakes legal battle with Nippon Shinyaku over commercialization rights, which remains a key point of uncertainty ahead of the August PDUFA date. The community is actively discussing the recent hiring of a new Chief Commercial Officer and the potential for a settlement, while maintaining strong conviction in the clinical data for Deramiocel.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in Sarnia, Canada.

Aduro Clean Technologies Inc

Aduro Clean Technologies is gaining significant momentum and attention following the strategic expansion of its Hydrochemolytic Technology into the paraffinic crude oil sector, bolstered by the appointment of a senior industry veteran to spearhead petroleum applications. Community discourse is heavily focused on this shift, with investors debating the potential for long-term commercialization and institutional accumulation while navigating ongoing discussions regarding the company's valuation versus its pre-revenue status.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as traders speculate on potential ecosystem expansion and increased institutional activity, fueling renewed interest in its data-ownership narrative. The community is actively debating the project's long-term utility while closely monitoring technical price levels amidst a notable surge in trading volume.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing significant volatility as investors debate whether the company can successfully scale production to meet the massive, AI-driven demand for its optical transceivers. While bullish traders are focused on aggressive call flow and the company's critical role as a supply bottleneck for hyperscale data centers, skeptics remain concerned about lofty valuations, persistent insider selling, and potential execution risks.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martin is trending as investors weigh its role in the U.S. government's record-breaking defense budget expansion and the broader rearmament trade amid ongoing geopolitical volatility. The community is actively discussing the stock's long-term backlog visibility and strategic value as a defense prime while monitoring how potential shifts in military procurement and supply chain demands influence its performance.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors debate the regulatory outlook for AXPAXLI, with active discussion surrounding the path to an NDA submission based on single-trial data versus the potential need for additional study results. Community sentiment remains polarized, pitting long-term holders betting on acquisition prospects and potential superiority over the current standard of care against skeptical voices highlighting competitive risks and recent legal challenges.

EchoStar Corp. engages in the design, development, and distribution of digital set-top boxes and products for direct-to-home satellite service providers. It operates through the following business segments: Pay-TV, Retail Wireless, and Broadband and Satellite Services. The Pay-TV segment business strategy is to be the best provider of video services in the United States by providing products with the best technology, outstanding customer service, and great value. The Retail Wireless segment offers Retail Wireless services as well as a competitive portfolio of wireless devices. The Broadband and Satellite Services segment business strategy is to maintain and improve leadership position and competitive advantage through development of technologies and services marketed to selected sectors within the consumer, enterprise and government markets globally. The company was founded by Charlie William Ergen, Candy Ergen, and James DeFranco in 1980 and is headquartered in Englewood, CO.

EchoStar Corp - Ordinary Shares - Class A

EchoStar Corp

EchoStar is gaining significant traction as investors treat the stock as a key proxy for SpaceX, driven by its substantial equity stake that appears undervalued relative to the upcoming IPO. The community is actively debating the potential for a short squeeze and asset repricing, closely monitoring upcoming milestones like the AT&T spectrum deal and the official SpaceX market debut.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last?

Adaptive Biotechnologies (ADPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment

PRTA posted a Q1 profit as a $50M Novo Nordisk milestone payment boosted revenue and improved its 2026 cash outlook.

Prothena Reports First Quarter 2026 Financial Results and Business Highlights

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2026 and provided business highlights. In the quarter we...

Prothena to Report First Quarter 2026 Financial Results on May 7

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...

Prothena (NASDAQ:PRTA) Shares Up 5.9% - Time to Buy?

Prothena (NASDAQ:PRTA) Trading Up 5.9% - Here's What Happened...

Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy

Prothena Corporation plc (NASDAQ:PRTA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to coramitug, a potential best-in-class amyloid depleter...

Prothena Corporation plc (NASDAQ:PRTA) Given Consensus Rating of "Hold" by Analysts

Shares of Prothena Corporation plc (NASDAQ:PRTA - Get Free Report) have earned a consensus rating of "Hold" from the eleven analysts that are covering the company, Marketbeat.com reports. Two...

Prothena (NASDAQ:PRTA) Share Price Passes Above 200-Day Moving Average - Time to Sell?

Prothena (NASDAQ:PRTA) Share Price Passes Above 200 Day Moving Average - Here's Why...

Prothena Announces Leadership Team Updates

AZN Posts Data From Hypophosphatasia Program on Efzimfotase Alfa

AstraZeneca reports phase III data showing efzimfotase alfa improves bone health in children with HPP, with mixed adult results and an overall favorable safety profile.

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

PRTAProthena Corporation plc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PRTA News